- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07605780
TAVI in LOW RISK in the REAL WORLD (TAVI IN LOW R)
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Severe aortic stenosis is the most common valvular heart disease worldwide. Its prevalence increases with age and is estimated to affect approximately 2% of the population aged 70-80 and as many as 9% of adults over 80 years of age.¹ Given the progressive aging of the population and the ever-increasing life expectancy, its prevalence will continue to rise, representing not only a topic of scientific interest but also a significant public health issue. In the past, the treatment of severe aortic stenosis was strictly the domain of cardiac surgery, and the gold standard was aortic valve replacement via open-heart surgery. In 2002, however, in an effort to offer a compassionate treatment option to patients considered high-risk or even ineligible for traditional surgery, transcatheter aortic valve replacement (TAVI) was introduced. The PARTNER study was the first randomized trial to evaluate the use of a balloon-expandable valve (Sapien - Edwards). The study consisted of two cohorts: Cohort A, comprising patients at high surgical risk, demonstrated that TAVI was non-inferior to SAVR in terms of 1-year all-cause mortality.
And a second cohort, Cohort B, which enrolled patients who were not considered suitable candidates for surgical aortic valve replacement (SAVR) and demonstrated a reduction in the rate of all-cause mortality or rehospitalization with transcatheter aortic valve implantation (TAVI) compared with standard medical therapy.² The efficacy and safety of transcatheter aortic valve replacement were quickly recognized by the ESC/EACTS and ACC/AHA, which incorporated this technique into their guidelines in 2012 and 2014, respectively. TAVI was in fact recommended as a Class I recommendation for patients ineligible for cardiac surgery and as a Class IIA recommendation for high-risk patients. At the same time, the CoreValve Extreme Risk Pivotal and CoreValve US Pivotal studies demonstrated the safety and efficacy of a self-expanding valve in the treatment of aortic stenosis (CoreValve - Medtronic); and in the second study, even its superiority over traditional surgery.
Since then, several studies have been conducted to demonstrate the safety and efficacy (non-inferiority) of TAVI compared to SAVR, even in intermediate-risk patients, including PARTNER 2 (which used a second-generation Sapien XT valve) and SURTAVI (CoreValve and Evolut R). Once again, guidelines were not long in coming, and in 2017, the ESC/EACTS classified the use of TAVI in patients with increased risk (intermediate or high) as Class I. Two further studies, PARTNER 3 and Evolut Low Risk, subsequently demonstrated the non-inferiority of TAVI compared to SAVR, thereby securing approval in Europe and the United States for use in low-risk patients. These valves have distinguished themselves by achieving excellent results across various outcomes in low-risk patients. In fact, Sapien 3 demonstrated superior results in terms of 1-year mortality and stroke rates and a lower need for pacemaker implantation compared to Evolut, which, however, achieved better hemodynamic performance within its own studies. Currently, registries showing TAVI outcomes in real-world patients are few and limited; therefore, it is important to assess whether data on outcomes in low-risk all-comers outside of trial settings align with trial results.
Patients included in the retrospective part of the study will be enrolled from January 2021 through September 2024 and will account for approximately two-thirds of the patients enrolled in the CCM.
Patients included in the prospective part of the study will be enrolled from October 2024 through August 2025.
For all patients deemed eligible, data will be collected regarding the screening/baseline visit, procedural data, discharge, and 12-month follow-up
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
BS
-
Brescia, BS, Italië, 25124
- Fondazione Poliambulanza Istituto Ospedaliero, Unità Emodinamica
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Patients aged 18 years or older
- Patients with severe symptomatic aortic valve stenosis undergoing TAVI.
- Patients considered to be at low surgical risk, defined as an STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) score of less than 4% and no major organ damage.
Exclusion Criteria:
- Patients who required emergency aortic valve replacement for any reason
- Need for conversion to SAVR during the procedure
- Patients who refused to consent to participate in the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Patients with symptomatic severe aortic valve stenosis
Consecutive patients with symptomatic severe aortic valve stenosis and low surgical risk-defined as an STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) of less than 4% and no major organ damage-who were treated with TAVI.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
All-cause mortality
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
|
Occurrence of stroke
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
|
Rehospitalization for cardiovascular causes
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Occurrence of major or minor bleeding
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
|
Implantation of a permanent pacemaker
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
|
Development of paroxysmal or permanent atrial fibrillation
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
|
Infectious causes requiring prolonged monitoring in the hospital
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
|
Presence of significant paravalvular or intravalvular regurgitation
Tijdsspanne: Up to 12 months
|
Up to 12 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NP1073
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .